BSE filing, NSE: MANGALAM. Summary written from the filing by ALFA Finder's alert engine.
Mangalam Drugs and Organics Ltd: key numbers
- Share price
- ₹29.10
- Market cap
- ₹46.06 Cr
- Revenue (annual)
- ₹232.1 Cr
- Net profit (annual)
- ₹-44.40 Cr
- P/E (TTM)
- -1.2×Sector 46.1×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mangalam Drugs and Organics Ltd
All →Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs issued a postal ballot notice seeking approval to re-appoint Praveen Saxena as independent director for a second five-year term. Voting closes 17 June 2026.
Mangalam Drugs and Organics Debt & Borrowing: ₹1,557 Cr
Mangalam Drugs and Organics Limited has reported a default amounting to Rs.1,557.27 Crore. The company has submitted a restructuring proposal to its banks to manage the obligation.
- Value
- ₹1,557 Cr
Mangalam Drugs and Organics Debt & Borrowing: ₹15.57 Cr
Mangalam Drugs and Organics Limited reported defaults on bank loan obligations totaling Rs. 15.57 Crore. The defaults involve cash credit accounts at Bank of Maharashtra and Bank of Baroda.
- Value
- ₹15.57 Cr
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs and Organics Limited has issued a Postal Ballot notice to seek shareholder approval for appointing Shri Prabhakar Raghunath Zavar as an Independent Director. The appointment is for five years.
Mangalam Drugs and Organics Management Change
Manglam Drugs and Organics Ltd. has appointed M/s S.N. Nanda & Co. as Statutory Auditor and M/s L.N. Joshi & Co. as Secretarial Auditor.
Mangalam Drugs and Organics Annual General Meeting
Mangalam Drugs and Organics Ltd held its 53rd Annual General Meeting on September 23, 2026. The meeting transacted standard business items including financial statement adoption and auditor appointments.
Other other announcement announcements
All →Infronics Systems Other Announcement
Infronics Systems appointed R & A Associates as Secretarial Auditor for FY 2026-27. This is a routine statutory appointment with no financial impact.
- Execution
- FY 2026-27
Onix Solar Energy Other Announcement
Onix Solar Energy's monitoring agency reports its rights issue proceeds are fully utilised. The report covers the quarter ended 30 September 2026.
Steamhouse India Other Announcement
Steamhouse India's Reg 32 statement confirms no deviation in IPO fund utilisation from prospectus objects for the quarter ended September 30, 2026. It also discloses a rectified issue-expense figure reallocating Rs 53.5 million to general corporate purposes.
Pine Labs Other Announcement
Pine Labs Limited filed CARE Ratings' Monitoring Agency Report for the quarter ended September 30, 2026, on its IPO proceeds. The report shows no deviation from objects and no major deviations.
Sihora Industries Other Announcement
Sihora Industries reported IPO proceeds utilisation of Rs.983.87 lakh of Rs.1,056 lakh raised, to September 2026. Shareholders approved the object deviation on 17 August 2026.
Titan Company Other Announcement
Titan's employee stock option trust transferred 19,385 shares worth Rs.8.40 Crore to eligible employees after PSU exercise. The off-market transfer was disclosed under PIT Reg 7(2).
- Value
- ₹8.40 Cr